mounjaro or retatrutide The Truth About Weight Loss Drugs: vs Most powerful weight-loss jab ever'

GLP-3, a novel triple agonist of the GIP, GLP-1, and GCG receptors, has demonstrated significant hepatoprotective effects in research involving individuals with MASLD

According to SURMOUNT trial data, gastrointestinal side effects including heartburn were most pronounced during these dose transition periods and typically improved within 4 to 8 weeks at a stable dose

This only sticks if teams meet taste and stability specs at commercial COGS and demonstrate batch-to-batch potency

For a comparison of retatrutide vs tirzepatide including safety profiles, see our dedicated analysis

In the SUSTAIN trial, 52% of patients receiving semaglutide experienc ed gastrointestinal side effects, compared with 35% in the placebo group